Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diazoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 known ✓ | Q14654 | 3/20 | 1.00 |
| ▸ | ABCC8 | Q09428 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diazoxide SCHEMBL31112206 | 1.00 | ABCC8 (1.00) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL721585 | 0.88 | ABCC8 (0.79) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL7950622 | 0.84 | ABCC8 (0.73) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL7604772 | 0.83 | ALDH1A1 (0.71) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL718987 | 0.83 | CYP3A4 (0.71) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL8286628 | 0.80 | ALDH1A1 (0.67) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL719962 | 0.80 | CYP3A4 (0.67) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL10724810 | 0.80 | ALDH1A1 (0.67) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL28084847 | 0.80 | ALDH1A1 (0.67) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA | |
| SCHEMBL718730 | 0.80 | CYP3A4 (0.67) | ABCC8KCNJ11ALDH1A1CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15203 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070304-A | High concentration formulations for anti-insulin receptor antibodies and uses thereof | 瑞泽乐特公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-12589098-B2 | Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a KATP channel opener | SEDOGEN LLC (US) | 2026-03-31 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| US-20260070972-A1 | MODULATORS | XOMA US LLC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260070996-A1 | FORMULATIONS FOR ANTI-INSULIN RECEPTOR ANTIBODY AND USES THEREOF | REZOLUTE INC (US) | 2026-03-12 | — | — | US | claimed |
| US-4396616-A | DIURETICS, ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1983-08-02 | — | — | US | claimed |
| EP-0083923-A2 | Aminoacyl-containing dipeptide derivatives useful as antihypertensives | MERCK & CO. INC. (US) | 1983-07-20 | — | — | EP | claimed |
| EP-0081094-A1 | Substituted omega-amino-carboxymethyldipeptide antihypertensive agents | MERCK & CO. INC. (US) | 1983-06-15 | — | — | EP | claimed |
| EP-0079522-A1 | N-Carboxymethyl(amidino)lysyl-proline antihypertensive agents | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| EP-0061186-A1 | Dipeptides containing thialysine and homologs as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | claimed |
| EP-0061187-A1 | Bicyclic lactams as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | claimed |
| EP-0049842-A2 | Substituted enantholactam derivatives, a process for the preparation and a pharmaceutical composition useful in the treatment of hypertension comprising the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-21 | — | — | EP | claimed |
| EP-0049505-A2 | Substituted caprolactam derivatives, a process for preparing and a pharmaceutical composition containing the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | claimed |
| EP-0046289-A2 | Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |